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Abstract
The mechanisms for the establishment and the persistence of the latent HIV-1 reservoir remain to be completely defined.
HIV-1 infection is characterised by the integration of the reverse transcribed proviral DNA into the host‘s genome. This
integrated proviral DNA can remain replication silent, but a small part of it is fully competent to restart viral replication
when treatment is interrupted. Hence, this replication-competent provirus is the cause of viral rebound and is called the
viral reservoir. The exact site of proviral integration within the host‘s cellular chromosome may affect the transcriptional
activity of HIV. Thanks to recent technological advances, HIV-1 integration site analysis has been used to assess HIV-1
reservoirs in HIV-infected individuals. Analysis of HIV-1 integration sites in infected individuals undergoing suppressive
ART led to identification of expanded clonal cell populations, indicating that clonal proliferation of the proviral reservoir
may contribute to the long-term persistence of viral reservoirs. Here we describe the findings of several clinical studies,
where a comprehensive HIV-1 integration site analysis was performed.
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Introduction
The most crucial step in the life cycle of a retrovirus is the
integration of the viral DNA into the host genome of an infected
cell. After integration, the provirus becomes an integral part of
the cell genome. Hence, its fate is closely linked to that of the
infected cell. Retroviruses persist in a host for the lifetime of the
infected cells and in their daughter cells during cycles of cell
division. Thus, the integration site is critical for both the virus and
its host, since it can affect the transcriptions of the integrated
provirus and of the host genes. The integration of the proviral
DNA is a unique event. Several studies show that the integration
of HIV-1 occurs randomly but it is biased towards transcriptionally
active genes, which in turn may promote efficient viral gene
expression [1].
A recent study by Marini and colleagues, offers an explanation
for HIV-1 integration site preferences [2]. The study results show
that the three-dimensional composition of the cell nucleus dictates
the gene regions that are most rapidly accessible to HIV-1. Upon
entry into the nucleus, the virus was shown to choose the nearest
options, which are areas located on the periphery of the nucleus.
Also, a strong bias against integration into genes located more
centrally was reported. In addition to the location, the authors’
suggestion is that the virus integrates into the first open chromatin
regions it meets along its route into the nucleus, i.e. into actively
transcribed genes. The authors also confirm previous findings that
the functional viral integrase and the presence of the cellular
Nup153 and LEDGF/p75 integration co-factors are indispensable
for the peripheral integration of the virus [2–4].
In the past, it was thought that HIV-1 latency might reflect HIV-1
integration into chromosomal sites that repress viral transcription
or that HIV-1 integration itself may result with transcriptional
repression. Later on, it was shown that the absence of virus
production in resting CD4+ T cells with integrated HIV-1 could
not be attributed to integration into chromosomal regions that
intrinsically repress transcription [5].
The early research on HIV integration sites and HIV persistence
focused more on HIV-1 integration sites and the effects on the
viral transcriptional activity and fate of the virus itself. Conversely,
the latest research examines the effect of HIV-1 integration on
the fate of the infected cells, the cells’ machinery and survival
mechanisms, and the contribution to the maintenance of the latent
reservoir [6,7].
HIV-1 integration site analysis using
patient material
The early research performed by Ikeda and colleagues showed that
infected resting CD4+T cells from two HIV-1 patients on long-term
successful ART harboured clusters of integration sites in cancer-
related genes [5]. More interestingly, in the same study, HIV-1-
infected cells with multiple identical integration sites were shown
in longitudinal analysis of samples from three patients. These
results led the authors to suggest that a plausible clonal T cell
expansion may be occurring.
Maldarelli and colleagues recently confirmed these findings. Using
a deep sequencing integration site sequencing method, they
identified 2410 HIV-1 integration sites in CD4+ T cells from five
patients receiving ART. Remarkably, 40% of HIV-1 integrations
were found to be identical, hence, coming from clonally proliferated
cells. Some of the cells were shown to have HIV-1 integration sites
in specific genes, which are known to promote cell survival and
expansion. One patient stood out, as approximately 50% of the
infected cells had the same integration site, indicating that all
sequences come from a single clone [6].
Concurrently with the report of Maldarelli and colleagues, a parallel
pivotal study from Wagner and colleagues came to similar
conclusions, using the integration site loop amplification technique,
which provides a method to link integration sites with Env
sequences of single proviral clones. This study demonstrated that
the chromosomal HIV-1 integration site in an infected cell‘s
genome may promote cell growth and contribute to persistence
in the absence of viral replication [7]. In this study, a total of 534
HIV-1 integration sites from three patients were investigated, and
identical viral sequences integrated at the same position in multiple
cells were found in each participant. HIV-1 integrations were
overrepresented in genes associated with cancer and 12 genes
were identified across multiple participants. The analysis was
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performed on longitudinal samples, where a greater proportion
of persisting proviruses were detected in proliferating cells [7].
The latest study by Cohn and colleagues added another piece to
the puzzle on HIV-1 reservoir maintenance in patients on ART by
comparing HIV-1 integration in viraemic controllers, untreated and
treated progressors, with longitudinal samples before and after
ART [8]. Cohn et al. reported that the majority of integration sites
were derived from proliferating clones of infected cells and their
number increased with time on ART. More interestingly, none of
the expanded T cell clones contained intact HIV-1 sequences. In
contrast, they report a decrease over time of the number of cells
bearing unique integration sites that were found to produce
replication-competent virus. The study results further showed that
the surviving cells were enriched for HIV-1 integration in silent
regions of the genome. Based on these findings, the authors
suggest that dividing, clonally expanded T cells contain defective
proviruses, and that the replication-competent HIV-1 reservoir is
primarily found in CD4+ T cells that remain relatively quiescent
[8]. In contrast, a recent study on longitudinal blood and tissue
samples from one HIV-1 positive patient by Simonetti and
colleagues, revealed that clonally expanded cells contained an
intact, infectious provirus that persisted and was able to produce
replication-competent virus. Because of these conflicting findings,
studies including higher numbers of patients will be necessary to
estimate the frequency of clonally expanded populations that carry
replication-competent HIV-1 to better understand the latent
reservoirs [9].
HIV-1 persistence mechanism: the obstacle to a
cure for HIV-1
The mechanism of HIV-1 reservoir persistence remains an important
topic of a constant debate. It remains to be confirmed whether
the maintenance of HIV is a result of ongoing low-level replication
in sanctuary sites, of clonal T cell proliferation, or of both
mechanisms combined. The three latest integration site studies
are the most pivotal studies that identify and describe HIV-1
integration sites in patients on ART [6–8]. These studies provided
proof of concept for the maintenance of reservoirs in patients
under optimal ART, in the absence of ongoing low-level HIV-1
replication.
On one hand, ongoing HIV-1 replication in ART-adherent HIV-
infected individuals has been considered unlikely by many authors
because of a lack of viral genetic divergence over time, and the
lack of emerging drug resistance mutations [10]. This is supported
by studies showing that even after long-term ART, identical variants
of HIV-1 are found in the blood [11] and in the lymph node tissue
in virally suppressed patients [12], suggesting that clonal expansion
is the main mechanism of viral persistence, with no evidence for
low-level viral replication in tissue sites.
On the other hand, most studies only examined viral sequences
derived from the blood compartment [13]. The findings from the
blood compartment might not necessarily be applicable to other
body compartments, particularly to lymphoid tissue where the
frequency of infection per cell is mostly higher [14] and the
intracellular drug concentrations are lower compared to the blood
[15]. Under low drug concentrations, the virus can continue to
replicate and evolve in these sanctuary sites within the reservoir
of cells in lymphoid tissue, and remain undetectable in the
bloodstream for a time, depending on the viral population
migration dynamics between these two compartments. Indeed,
a recent mathematical modelling of HIV-1 spatial dynamics
between blood and lymph node tissues, based on pol sequencing
data from three patients, showed that production of partially
drug-resistant strains cannot become dominant in the sanctuary
sites, because of the competition with the drug-sensitive strains
in the absence of the drugs [14].
Conclusions
The new knowledge that HIV-1 integration site analyses have
provided combined with the anticipated research, will guide the
design of optimal HIV-1 cure approaches. Hence, HIV-1 cure
strategies may need to focus on two major aspects: (1) to prevent
ongoing low-level HIV-1 replication in presence of ART; and (2)
to prevent clonal T cell expansion of already-infected cells.
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